Home Genetic Testing Basics Genetic Variant Test: Pathogenic, Benign, VUS, and Results Explained

Genetic Testing Basics

Genetic Variant Test: Pathogenic, Benign, VUS, and Results Explained

July 31, 2026 Modified date: July 31, 2026

Understand pathogenic, likely pathogenic, benign, likely benign, and VUS genetic test results, including classification evidence, family testing, and reclassification.

A genetic variant test identifies differences in DNA and evaluates whether they are likely to affect health. The test may target one known family variant, sequence a single gene, examine a multigene panel, or analyze exome or genome data. The laboratory then classifies relevant findings as pathogenic, likely pathogenic, uncertain, likely benign, or benign. These categories describe the strength of evidence that a variant causes disease; they do not describe how severe a person’s symptoms will be.

A pathogenic or likely pathogenic finding can confirm a diagnosis or inherited risk when it fits the gene, condition, and inheritance pattern. A benign result represents normal human variation. A variant of uncertain significance, or VUS, sits between these groups because available evidence is incomplete or conflicting. A VUS is not a confirmed harmful variant and usually should not direct major treatment or preventive surgery. Accurate interpretation requires the full report, personal and family history, the laboratory method, and sometimes testing of selected relatives.

Pathogenic and likely pathogenic variants may support medical action when they match the clinical condition and inheritance pattern.
Benign and likely benign variants are not considered causes of the tested disorder.
A VUS is an unresolved finding, not a positive diagnosis or a “partial mutation.”
Variant classification measures evidence of disease causation, not expected symptom severity.
Different laboratories may classify the same variant differently because they use different evidence, dates, or gene-specific rules.
Reclassification can occur as new population, family, functional, and clinical data become available.

What a Genetic Variant Test Finds
The Five Main Variant Classifications
How Laboratories Classify Variants
What Pathogenic and Likely Pathogenic Mean
What Benign, Likely Benign, and VUS Mean
Inheritance, Phenotype, and Family Testing
Reclassification and Laboratory Differences
How to Use the Result Safely

What a Genetic Variant Test Finds

A genetic variant is a difference between a person’s DNA sequence and a reference sequence. Everyone carries millions of variants. Most contribute to ordinary human diversity or have no known health effect. A clinical test filters this variation to find changes relevant to a specific medical question.

The phrase “genetic variant test” can refer to several scopes:

Targeted familial-variant testing: looks only for a specific change already identified in a relative.
Single-gene testing: searches one gene for sequence changes and often deletions or duplications.
Multigene panel testing: examines several genes associated with a condition or symptom group.
Exome sequencing: analyzes most protein-coding regions across the genome.
Genome sequencing: analyzes coding and noncoding DNA more broadly.
Specialized testing: detects repeat expansions, methylation changes, mitochondrial variants, or structural rearrangements.

The laboratory may find substitutions, insertions, deletions, copy-number changes, splice alterations, repeat expansions, or other variant types. Each finding must be interpreted in relation to the gene’s normal function and the mechanism known to cause the disease.

A variant that stops production of a protein may be harmful in a gene where loss of one working copy causes disease. The same kind of stop variant may be harmless in another gene where loss of function is tolerated or where disease occurs through a different mechanism. Variant type alone is therefore not enough.

The test’s purpose also shapes interpretation. A pathogenic germline variant may explain an inherited disorder or future disease risk. A somatic variant found only in a tumor may guide treatment without being inherited. A pharmacogenetic variant may affect drug metabolism but not cause a disease. The report should clearly state the clinical context.

Testing is most informative when the ordering clinician provides detailed symptoms, age of onset, laboratory findings, imaging, pathology, family history, and suspected inheritance. A diagnostic genetic test result cannot be interpreted safely from the DNA label alone.

The Five Main Variant Classifications

Clinical laboratories commonly use a five-category system for inherited sequence variants. The categories represent a spectrum of evidence.

Classification	General meaning	Usual clinical role
Pathogenic	Strong evidence that the variant causes disease	May confirm a diagnosis or inherited risk when clinically relevant
Likely pathogenic	Evidence strongly favors a disease-causing effect	Often used similarly to pathogenic findings with clinical correlation
Variant of uncertain significance	Evidence is insufficient or conflicting	Usually not used alone for medical intervention or predictive testing
Likely benign	Evidence strongly favors no disease-causing effect	Not considered an explanation for the tested condition
Benign	Strong evidence the variant does not cause the disorder	No disease-specific action based on the variant

“Likely” categories are not casual guesses. They indicate that the evidence crosses a defined threshold but does not reach the strongest level. Pathogenic and likely pathogenic variants are generally considered clinically actionable when the gene-disease relationship, phenotype, and inheritance fit.

The classification is about pathogenicity, not penetrance. A pathogenic variant can have incomplete penetrance, meaning some carriers never develop the condition. It can also have variable expressivity, meaning affected people differ in age of onset and severity. Conversely, a VUS could eventually prove harmful, but current evidence is not adequate to treat it as such.

Classification may differ for copy-number variants, somatic cancer variants, mitochondrial variants, and pharmacogenetic alleles. These findings use related but not always identical frameworks. The laboratory report should identify which system was applied.

The five categories also do not indicate whether a variant explains all of a person’s symptoms. A pathogenic finding in one gene may account for only part of a complex phenotype. Two diagnoses may coexist, or the result may be unrelated to the reason for testing.

How Laboratories Classify Variants

Variant classification combines several independent evidence types. Laboratories review population data, affected families, functional studies, computational predictions, gene mechanism, and the person’s clinical features. No single database or software score should determine the answer.

Population frequency

A variant that is common in healthy populations is unlikely to cause a very rare, severe dominant disorder with high penetrance. Frequency thresholds must match the condition’s prevalence, inheritance, penetrance, and genetic heterogeneity. Population databases also need ancestry diversity because a variant rare in one group may be common and benign in another.

Predicted molecular effect

Some variants are expected to disrupt a gene strongly, such as a frameshift or early stop variant. This evidence is useful only when loss of function is an established disease mechanism for that gene and the altered region is biologically important.

Missense variants change one amino acid and are harder to interpret. The position, protein domain, conservation, known variants at the same site, and validated computational tools may contribute evidence. Prediction software supports classification but does not replace clinical or laboratory data.

Functional studies

Well-designed experiments can show whether a variant changes protein activity, RNA splicing, cellular localization, or another relevant function. The study must reflect the disease mechanism and include proper controls. A poorly validated assay can mislead classification.

Family segregation

A variant that tracks with disease across several relatives may support pathogenicity. A variant found in healthy older relatives may support a benign interpretation for a highly penetrant condition. Family size, age, incomplete penetrance, and accurate diagnosis all affect the strength of this evidence.

De novo occurrence

A variant found in an affected child but absent from both biological parents can support pathogenicity, particularly for a specific severe dominant condition. Parentage, sample identity, mosaicism, and phenotype specificity must be considered.

Clinical and published evidence

Reports of the same variant in unrelated affected people can add evidence when cases are well described and not duplicated across publications. Databases such as ClinVar collect laboratory interpretations, but a database entry is not automatically correct. Expert-panel review and transparent evidence carry more weight than an unsupported assertion.

ClinGen develops gene- and disease-specific refinements to the general classification framework. These specifications improve consistency because a frequency threshold or functional assay appropriate for one gene may not work for another.

What Pathogenic and Likely Pathogenic Mean

A pathogenic or likely pathogenic result can be clinically important, but its meaning depends on the testing scenario.

In a person with symptoms

The finding may confirm a diagnosis when the variant occurs in a gene known to cause the suspected condition and the inheritance pattern fits. For an autosomal dominant disorder, one pathogenic variant may be sufficient. For an autosomal recessive disorder, two disease-causing variants are generally needed, often with evidence that they are on opposite gene copies.

A positive result may guide treatment, surveillance, specialist referral, or avoidance of specific risks. It can also stop unnecessary testing and provide access to condition-specific resources.

In a person without symptoms

The result may indicate predictive or presymptomatic risk. The report should describe penetrance, typical age range, sex-related effects, and recommended surveillance. A pathogenic variant does not always mean disease is inevitable.

For example, some hereditary cancer variants raise lifetime risk substantially without guaranteeing cancer. Some cardiomyopathy variants require periodic imaging because structural disease may appear later. The person’s age and family history affect the current risk estimate.

In carrier testing

One pathogenic variant in an autosomal recessive gene usually indicates carrier status rather than disease. The reproductive partner may be offered testing. If both partners carry pathogenic variants in the same gene, each pregnancy usually has a 25% chance of being affected.

In a tumor

A pathogenic tumor variant may be acquired and limited to cancer cells. It may predict response to a targeted therapy or clarify diagnosis. It does not establish inherited risk unless separate germline testing confirms the variant in a non-tumor sample.

Confirmation and fit

Unexpected results may require confirmation with a second sample or method. A variant should not be assumed to explain the patient merely because the laboratory calls it pathogenic. The phenotype, inheritance, zygosity, phase, and gene-disease relationship must align.

What Benign, Likely Benign, and VUS Mean

Benign and likely benign variants are part of normal genetic variation. They are not considered causes of the tested condition. Many laboratories do not list them in the main clinical report because doing so would add volume without helping care.

A VUS is different. It is a variant for which the evidence cannot support either a disease-causing or benign classification. Reasons include:

The variant is rare and has not been seen in enough people.
Published cases are few, poorly described, or contradictory.
Functional data are missing or unreliable.
Computational predictions disagree.
The gene’s disease relationship is incomplete.
The variant appears in both affected and unaffected people without a clear pattern.
Population data are limited for the person’s ancestry.

A VUS is not “almost pathogenic,” and the five-category system is not a numerical progression in which uncertainty automatically leans toward harm. Many uncertain variants are later downgraded to likely benign or benign, though some are upgraded.

Medical management should usually be based on the person’s symptoms, clinical diagnosis, and family history rather than the VUS. A VUS should not by itself justify preventive organ removal, termination of pregnancy, or testing healthy relatives as if they were at confirmed risk.

The 2026 ACMG statement on VUS reporting emphasizes that laboratories should consider whether reporting an uncertain variant is likely to help answer the clinical question. Broad testing in people with low pretest probability can generate uncertainty without benefit. Reports should provide clear language, avoid overstating a VUS, and explain whether follow-up studies could be useful.

A detailed discussion of uncertainty is available in the variant of uncertain significance guide.

Inheritance, Phenotype, and Family Testing

The same variant can have different implications depending on zygosity and inheritance. Zygosity describes whether the variant is present in one or both gene copies. Phase describes whether two variants are on the same copy or opposite copies.

For an autosomal dominant disorder, one disease-causing variant may be sufficient, but incomplete penetrance can leave some relatives unaffected. For an autosomal recessive condition, two pathogenic variants usually need to be in trans. If both variants are in cis on the same chromosome, the person may be only a carrier.

X-linked findings differ according to the gene, chromosome complement, and X-inactivation. Mitochondrial variants can be present at different proportions, called heteroplasmy, across tissues and relatives. These patterns affect risk and severity.

Family testing can answer focused questions:

Did the variant arise de novo in the affected person?
Does it segregate with disease across relatives?
Are two recessive variants on opposite gene copies?
Which relatives carry a confirmed pathogenic family variant?
Is an apparently healthy carrier old enough for nonpenetrance to be informative?

Testing should be strategic. For a VUS, the laboratory may identify which relatives would add evidence. Randomly testing many healthy relatives can create confusion and may not change classification.

Phenotype information is equally important. A highly specific clinical feature can support a variant in the correct gene. A poor match may suggest that the finding is incidental, only partially explanatory, or misclassified. Updated records should be sent to the laboratory when new symptoms emerge.

Testing an affected relative first is often the strongest approach in a family. Once a pathogenic variant is identified, other relatives can receive a targeted variant test rather than repeating broad sequencing.

Reclassification and Laboratory Differences

Variant classifications can change because science changes. New population databases, expert-panel rules, functional studies, family cases, and improved computational tools may shift the evidence.

Reclassification is most common for uncertain findings. A VUS may move to likely benign, benign, likely pathogenic, or pathogenic. Pathogenic and benign classifications can also change, though less often. The clinical impact depends on the direction of change and whether care was based on the original report.

Different laboratories may disagree because they:

Reviewed the variant on different dates.
Used different internal patient data.
Applied different evidence strengths or gene-specific rules.
Interpreted the phenotype differently.
Had access to unpublished family or functional information.
Used different transcript or reference-sequence conventions.

A conflict does not necessarily mean one laboratory was careless. It signals that the evidence needs comparison. A genetics professional can request the supporting criteria, check ClinVar submissions, ask whether expert-panel guidance exists, and determine whether a formal review is warranted.

Clinical cohort studies show that reclassification is not rare over long periods, although most tested variants do not change. Changes can be meaningful: an upgrade may establish a diagnosis or family-testing pathway, while a downgrade may remove an assumed risk.

Laboratories vary in recontact policy. Some issue amended reports to the ordering clinician; others require a request. Patients should keep current contact information with the clinic and ask whether reevaluation occurs automatically.

Reevaluation reviews the interpretation of a known variant. Reanalysis returns to a larger sequencing dataset and looks again for relevant findings, including newly discovered disease genes. These are separate services and may have different costs or timelines.

How to Use the Result Safely

The safest interpretation begins with the complete report rather than a portal summary. Record the gene, exact variant notation, transcript, zygosity, classification, condition, laboratory, and report date.

Ask the ordering clinician or genetics professional:

Why was this variant reported?
Does it fit the symptoms and family history?
Is the gene-disease relationship established?
Is the result germline, somatic, mitochondrial, or pharmacogenetic?
Does the inheritance pattern fit?
Is confirmation needed?
What medical action is supported now?
Which relatives, if any, should be tested?
Would family studies help a VUS?
Who will communicate a reclassification?
When should reevaluation or broader testing be considered?

For a pathogenic or likely pathogenic result, follow condition-specific guidance. The action may include surveillance, treatment, reproductive counseling, or targeted testing of relatives. Do not assume every pathogenic variant requires the same intervention.

For a negative result, review the test’s limitations and residual risk. The test may not have assessed every variant type or disease gene. Clinical care may still be based on symptoms or family history.

For a VUS, avoid irreversible action based on the uncertain finding alone. Keep the report, update the clinic if family history changes, and ask whether selected family testing or reanalysis could help. Continue ordinary care based on established risk factors.

Consumer raw-data files and third-party variant interpretations deserve caution. Genotyping errors, strand orientation, outdated databases, and automated predictions can create false alarms. A clinically important consumer finding should be confirmed in an accredited clinical laboratory and interpreted in context.

Variant classification is a structured evidence process, not a verdict about a person’s future. Pathogenic findings can be useful without being perfectly predictive. Benign findings can be ignored for the tested disorder. A VUS can be documented without being acted on. The report becomes medically meaningful only when its evidence, scope, inheritance, and clinical fit are understood together.

References

Disclaimer

Variant classifications must be interpreted with the test method, clinical findings, inheritance pattern, and current evidence. Do not change treatment, surgery, surveillance, or reproductive plans based only on a VUS or an unconfirmed consumer result. Review important findings with the ordering clinician or a qualified genetics professional.

Table of Contents